Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:43:04.446Z.
Consensus retrieved: 2026-10-06T14:46:07.343Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:43:04.446Z.
Quote observation: 2026-10-06T15:40:33.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4efcc2f75e7b9d1a3dd193370b83b229becf15f1f7fcdbde4bbae966de3ea950
Forward PE Ratio (N/A) = Dated Quote Price ($8.21) / Consensus Forward EPS ($-2.39)
FORWARD PE RATIO
N/A
Olema Pharmaceuticals, Inc.
Market Cap
$717.56M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | $717.56M | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $720.79M | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $725.14M | N/A |
| Avalo Therapeutics, Inc. (AVTX)vs › | $728.23M | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $702.99M | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $740.17M | N/A |
| Annexon, Inc. (ANNX)vs › | $691.60M | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $747.84M | N/A |
| Helus Pharma Inc. (HELP)vs › | $685.97M | N/A |
| Candel Therapeutics, Inc. (CADL)vs › | $752.48M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $8.21, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.39 | $-2.41 – $-2.33 | 6 | n/m |
| 2027-12-31 | $-2.66 | $-3.03 – $-2.44 | 7 | n/m |
| 2028-12-31 | $-2.24 | $-2.90 – $-1.91 | 6 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
